A Dividend Raise 7 Years in the Making

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

It's sad when keeping revenue "about the same" as last year is seen as a healthy situation, but such is the life for the pharmaceutical industry.

Merck (NYSE: MRK  ) will see generic competition for its top-selling allergy and asthma drug Singulair next August, so making up for that lost revenue and keeping 2012 revenue equal to this year should be seen as a solid win. Singulair is a $5 billion drug, after all.

Over the next two years, Merck plans to seek Food and Drug Administration approval for eight more medications on top of the five approvals it received this year. The drugs' treatments run the gamut from chronic insomnia to hardening of the arteries to osteoporosis, and there's even an improved version of its cervical-cancer vaccine Gardasil. There are also two allergy medicines to replace Singulair. Merck's investors can thank the timely purchase of Schering-Plough for many of the drugs, including an anesthesia-reversal drug, Bridion, which has been years in the making.

There are no guarantees that the drugs will be approved -- this is the FDA, after all -- and there's no guarantees that doctors will prescribe them even if they are approved. Witness Merck's new hepatitis C drug Victrelis' inability to compete with Vertex Pharmaceuticals' (Nasdaq: VRTX  ) Incivek.

But Merck certainly doesn't look like it's worried about its ability to create cash flows. For the first time since it lost Vioxx in 2004, Merck raised its dividend. And it wasn't a token raise, either; the 10.5% increase to $0.42 per quarter gives Merck a dividend yield of 4.7%. That's juicier than Pfizer (NYSE: PFE  ) , Johnson & Johnson (NYSE: JNJ  ) , and Bristol-Myers Squibb (NYSE: BMY  ) .

You can still get a larger income with Eli Lilly (NYSE: LLY  ) , but you're probably sacrificing growth potential to get it. And remember, this is the pharmaceutical industry, so a lack of growth is actually a decline.

Looking for more dividend ideas? Check out the Fool's new free report "Secure Your Future With 11 Rock-Solid Dividend Stocks."

Fool contributor Brian Orelli holds no position in any company mentioned. Check out his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson, Pfizer, and Vertex Pharmaceuticals and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (8)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1588375, ~/Articles/ArticleHandler.aspx, 10/25/2016 5:15:50 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 7 hours ago Sponsored by:
DOW 18,223.03 77.32 0.43%
S&P 500 2,151.33 10.17 0.47%
NASD 5,309.83 52.43 1.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/24/2016 4:01 PM
BMY $49.23 Down -0.79 -1.58%
Bristol-Myers Squi… CAPS Rating: ****
JNJ $113.61 Up +0.17 +0.15%
Johnson and Johnso… CAPS Rating: ****
LLY $77.57 Down -0.68 -0.87%
Eli Lilly and Co. CAPS Rating: ***
MRK $60.75 Down -0.45 -0.74%
Merck and Co. CAPS Rating: ****
PFE $32.13 Down -0.05 -0.16%
Pfizer CAPS Rating: ****
VRTX $78.73 Down -2.03 -2.51%
Vertex Pharmaceuti… CAPS Rating: ****